AxoGen (NASDAQ:AXGN) Reaches New 12-Month High – Still a Buy?

AxoGen, Inc. (NASDAQ:AXGN)’s stock price reached a new 52-week high during trading on Friday . The company traded as high as $19.19 and last traded at $18.87, with a volume of 91274 shares changing hands. The stock had previously closed at $18.50.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group increased their price target on shares of AxoGen from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, February 3rd.

AxoGen Trading Down 2.7 %

The company has a market cap of $792.18 million, a P/E ratio of -56.25 and a beta of 1.00. The stock’s 50-day moving average is $17.29 and its two-hundred day moving average is $14.77. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. R Squared Ltd bought a new position in AxoGen during the fourth quarter valued at approximately $30,000. US Bancorp DE bought a new position in AxoGen during the fourth quarter valued at approximately $30,000. State of Wyoming bought a new position in AxoGen during the fourth quarter valued at approximately $31,000. Quest Partners LLC lifted its position in AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 2,076 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new position in AxoGen during the fourth quarter valued at approximately $93,000. Institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.